Form 4: Dexcom Executive Matthew Dolan Sells Shares Under 10b5-1 Plan

Matthew Dolan, EVP of Strategy & Corporate Development at Dexcom Inc., sold shares of common stock on March 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 15, 2024, Matthew Dolan, the EVP of Strategy & Corporate Development at Dexcom Inc., sold shares of Dexcom's common stock.
• The sales were executed under a 10b5-1 trading plan adopted on December 15, 2023.
• A total of 4,203 shares were sold in multiple transactions at weighted average prices of $129.1842, $130.7704, and $131.3912.
• Following the reported transactions, Dolan beneficially owns 44,367 shares of Dexcom common stock.
• This number includes 40,075 unvested restricted stock units that will vest through March 8, 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing 10b5-1 plan, which is a common practice. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are often pre-scheduled for personal financial planning. It's important to consider the overall insider sentiment and company performance when evaluating the significance of such transactions.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small volume of shares sold.

Key Dates